Relmada Therapeutics, Inc. Banner Image

Relmada Therapeutics, Inc. has reached its limit for free report views

Work for Relmada Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Relmada Therapeutics, Inc.

  • Ticker RLMD
    Exchange NASDAQ More
  • Industry Drug Manufacturers - Other More
  • Sector Healthcare More
Relmada Therapeutics, Inc. Logo Image
  • 1-10 Employees
  • Based in New York City, New York
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, REL-1017 (dextromethadone) is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonistsMore may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
Relmada Therapeutics, Inc.

Most Recent Annual Report

Relmada Therapeutics, Inc. MOST RECENT 2019 Form 10K

Report Locked. Relmada Therapeutics, Inc. has reached its limit for free report views.